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Abstract 
The primary vascular access options for the hemodialysis population are arteriovenous 
fistulas (AVF), arteriovenous grafts (AVG) and cuffed central venous catheters (CVC). 
AVFs are associated with the most favorable outcomes with respect to complications, 
interventions required to maintain functionality and patency as well as overall cost. These 
population-based outcomes, in conjunction with the efforts of the Fistula First 
Breakthrough Initiative (FFBI), have propelled the prevalence of AVFs in the United 
States hemodialysis population. While this endeavor remains steadfast in assuring the 
continued dominance of this policy for AVF preference, it fails to take into account a 
subset of the dialysis population who will fail to see the benefits of an AVF. This subset 
of patients may include the elderly, those with poor vasculature anatomy, those with 
slowly progressive CKD that are more likely to die than progress to ESRD, and those 
with an overall poor long-term prognosis and shortened life expectancy. Thus, in an 
effort to avoid numerous unnecessary surgical and interventional procedures with 
minimal to no gains in clinical outcomes, an individualized patient approach must be 
adopted. The CMS instituted quality incentive program (QIP) is designed to reward high 
AVF prevalence while also penalizing high CVC prevalence. The current model is 
devoid of case-based adjustment, thus penalties are disbursed to dialysis providers in 
accordance with a “one-size-fits-all” fistula only approach. The most suitable access for a 
patient remains the one that takes into account the characteristics unique to the individual 
patient with a primary focus on patient comfort, satisfaction, quality of life and clinical 
outcomes.        
Introduction  
 
Arteriovenous fistulas (AVFs), arteriovenous grafts (AVGs) and tunneled cuffed central 
venous catheters (CVCs) are the three main vascular accesses used for hemodialysis. 
When one attempts to identify the characteristics associated with the ideal vascular access 
for hemodialysis, a series of imperative factors emerges. Firstly, the access must be 
appropriately selected based on the patients’ overall characteristics (age, life expectancy, 
comorbidities, vascular anatomy, and personal preferences). Secondly, the access must be 
able to be consistently used for hemodialysis with minimal interventions, both surgical 
and endovascular, in order to maintain functionality. Third, it must be associated with the 
lowest infectious and thrombotic complication risk thus leading to the lowest associated 
costs. Finally and perhaps most importantly, it must offer superior patient survival and 
quality of life.   
 
In 2003, the Centers for Medicare & Medicaid Services (CMS) initiated the National 
Vascular Access Improvement Initiative, subsequently named the Fistula First 
Breakthrough Initiative (FFBI), and currently renamed Fistula First Catheter Last (FFCL) 
with the goal of increasing the use of AVFs among hemodialysis patients for whom an 
AVF was deemed a viable option. The goal established by CMS was to achieve an AVF 
use rate of at least 66% amongst all eligible hemodialysis patients in the United States.(1) 
This goal has indeed been realized with the use of AVF increasing from 62 percent in 
August of 2010 to 66.4 percent in April 2015 (Figure 1), with corresponding decreases in 
CVC use percentages from 18.1 to 15.1, respectively.(2) While this is an encouraging 
trend, the 2014 United States Renal Data System (USRDS) reports that 61 percent of patients with incident End Stage Renal Disease (ESRD) had a catheter alone as their primary vascular access at their first outpatient HD session and this CVC dominance 
persisted to the 90-day mark (Figure 2). When patients who had a maturing AVF or AVG are included in this analysis, a staggering 81 percent of patients were noted to be using a catheter at HD initiation.(3) Among those patients who began HD with a 
catheter, 36 percent were still using a catheter at 1 year, whereas 51 percent had 
transitioned to an AVF. Among patients who began HD with an AVF, 83 percent were 
still using an AVF at 1 year. This suggests that while placement of an AVF is possible in 
a majority of patients, there remains a cohort that does not succeed with this intervention. 
The recognition of these patients in whom the risks of an AVF outweigh the benefits 
requires the incorporation of a patient-centered approach to care with the elimination of a 
“one size fits all” approach. This approach allows for the acceptance of patients with 
advanced age, particular comorbid conditions or anatomical deficits in whom an AVF 
may not be the desired or most suitable option.(4-8).   
 
Despite the scenario described above, CMS instituted a quality incentive program (QIP) 
in 2012, with the incorporation of vascular access quality outcomes into its metric in 
2014, which rewards high AVF prevalence and penalizes high CVC prevalence. It should 
be noted that for payment year 2015, vascular access constitutes 25% of the total QIP 
score (9), which can indeed have a substantial financial impact. What is even more 
disheartening is that these rewards, penalties and percentage allocations are done so 
without regard for the individual patient context, such that the clinical characteristics and 
preferences of the patient remain unincorporated into the ultimate goals of care. Rosas 
and Feldman in a cost-utility analysis concluded that the high risk of complications of 
temporary catheters as a bridge to AVF functionality and the overall low AVF maturation 
rate explains why a universal policy of fistula first for all incident dialysis patients may 
not optimize clinical outcomes.(10) They suggested that strong consideration should be 
given to a more patient-centered approach taking into account the likelihood of AVF 
maturation. It is precisely the “one size fits all approach” that has been an unfortunate 
misinterpretation of the goals set forth by the CMS and FFCL initiatives that this paper 
attempts to re-envision. 
 
Individual Patient Context 
 
The implications of the CMS QIP and the FFCL initiative are that catheter avoidance is 
either equally or more important than actual AVF use and this has led to the 
reconsideration of a “fistula only” approach. AVFs have a primary failure rate of 30-70% 
and a 1-year patency rate of 40-70%, with numerous procedures of varying success rates 
being frequently required to combat these outcomes (7, 11-13) leading to the vascular 
access dilemma faced by nephrologists.  This dilemma may offer an explanation as to 
why, despite the increasing use of AVF in prevalent hemodialysis patients, the majority 
of patients initiating hemodialysis in the United States do so with a CVC. Allon has 
suggested the need for change in the current Medicare reimbursement policies that may 
be perpetuating the high CVC prevalence in those initiating dialysis.(14)   
From a percentage allocation perspective it can be deduced that CMS acknowledges there 
are certain subsets of patients that are better suited for AVGs. Their goal of 66% AVF 
prevalence implies that the remaining 34% of patients may be better suited with another 
form of vascular access. The FFBI’s original goal was to decrease the CVC use to <10 
percent for patients on hemodialysis longer than 90 days (15-16) and so the remaining 
percentage of patients would be expected to obtain an AVG. A patient-centered approach 
to access management can be used to determine the proportion of the patient population 
who will reap the benefits of an AVF rather than be subjected to the risks of surgery and 
interventional procedures to place an AVF that will never function or allow the long-term 
benefits of an AVF to accrue. The “Triple Aim” of CMS is to improve the patient 
experience of care (including quality and satisfaction), improve the health of populations 
and reduce the per capita cost of health care.(17) The success of these objectives is more 
probable in a patient-centered approach to care.   
 
A patient-centered approach attempts to disrupt the current established vascular access 
paradigm, with the overall goal of providing patients with a functioning, complication 
free vascular access based on their unique clinical attributes.(4) This approach remains 
respectful of the fact that a reliable AVF likely offers the best clinical outcomes in the 
dialysis population as a whole but is also cognizant that there are indeed subsets of 
patients for whom an AVF may result in either adverse clinical outcomes or minimal to 
no superiority with regards to a risk versus benefit analysis.  
 
The Renal Physicians Association (RPA) via its vascular access initiative emphasizes the 
role of the nephrologist in driving change with respect to hemodialysis access.(18) The 
nephrologist plays a key role in providing guidance to vascular surgeons and 
interventionalists, and holding them accountable for improved vascular access outcomes. 
(19) In essence, the nephrologist’s role has to go beyond ensuring that every patient 
obtains an AVF; rather the nephrologist must evaluate which patient will benefit from an 
AVF versus an alternative form of vascular access.(19-20) The nephrologist should be 
right at the helm of the decision making process, driving a shared clinical dialogue 
between the patient, vascular surgeon and other members of the care team such that the 
patient’s long-term prognosis, renal progression, vascular anatomy, comfort, personal 
values and goals of care are all addressed.  
 
While the patient-centered approach must include factors unique to an individual patient 
or subgroups of patients, it must also be inclusive of the most important aspect of any 
personalized care based model, that of the patient’s perspective. The essence of patient 
centered care is a shared decision making process that requires that the patient and 
relevant family members receive unbiased education and that their values and wishes are 
then the driver of all important clinical decision making (21). Many studies address the 
importance of a multidisciplinary approach to hemodialysis vascular access placement 
and management.(22-23) The members of these multidisciplinary teams include 
nephrologists, interventional nephrologists/radiologists, nephrology nurses, vascular 
surgeons and physician assistants. The center of this team should include the patient as 
he/she represents the most important member of any multidisciplinary approach.  
 Casey et al performed a systematic review to address the patient’s perspectives on 
hemodialysis vascular access.(24) They identified six themes which encompass the 
domains of interest to these patients (Table 1). These themes allow the provider to 
understand the despair often felt by patients undergoing this mental, physical and clinical 
transition. It is the responsibility of the healthcare provider to educate and counsel these 
patients in order to provide support is dealing with these crucial domains.  
   
In an attempt to update their vascular access guidelines, European Renal Best Practice 
Workgroup surveyed a panel of kidney patients, nephrologists, nurses, surgeons and 
radiologists. The objective of this study was to compare the views of the patients and 
clinicians with respect to the priority of access-related decisions. They discovered that 
patients assigned higher priority to decisions regarding managing adverse effects of 
arteriovenous access and patient involvement in care, while clinicians prioritized 
decisions around sustaining patients' access options, technical aspects of access creation, 
and optimizing fistula maturation and patency.(25) It should come as no surprise that 
patients and clinicians have differing concerns; however it should reinforce the necessity 
of shared decision making in order to establish a unified plan that is in line with the 
wishes and best interests of the patients.   
  
Investigators from Wake Forest University conducted a prospective study to explore 
patients' desired versus experienced roles in treatment decisions, characterize perceptions 
of treatment outcomes, and identify important sources of information with respect to 
vascular procedures. Of the patients who had dialysis accesses placed, about a quarter felt 
confused or overloaded with the amount of information that they were provided and 
about half said that they only had one treatment recommended to them without 
alternative choices.(26) 
 
Shared decision making between patients and clinicians should take into account the 
patients’ long-term prognosis, goals of care and vascular anatomy. The patient needs to 
fully understand the risks, benefits and burdens of vascular access placement and 
hemodialysis. It is only via this shared decision/patient centered model that a benefit can 
truly be conferred on the patient.  
 
The Aging Dialysis Population 
  
Based on the 2014 USRDS report, individuals aged 75 and older represent 25.5% and 
21.9% of all incident and prevalent HD patients, respectively.(3) The prevalence per million continues to increase in all age groups, with the relative magnitude of increase from 2000 to 2012 greater in older (>75) age groups.(3) When dealing with 
this population principal factors that must be taken into consideration are quality of life 
and life expectancy as age-matched survival is poorer compared to people not on dialysis. 
(27)  Studies have shown that dialysis may not confer a survival advantage in patients 
with renal failure with two or more of the following: age 75 years or older, high 
comorbidity scores, marked functional impairment or severe chronic malnutrition.(28-37) 
While a discussion of whether renal replacement therapy should be offered to this 
population is beyond the scope of this article, it should be recognized that alterations in 
treatment algorithms must occur in order to provide the most appropriate therapy for this 
population.  
 
Should the same “standard of care,” i.e. FFCL, be applied to this population of dialysis 
patients? Moreover, if the same benefits conveyed to the younger cohort of dialysis 
patients are not transferable to this population, then should a case-mix adjustment for age 
exist in the QIP measures for vascular access? These questions must be addressed given 
that the majority of patients initiating hemodialysis do so with a CVC.(3)  
   
 
The dialysis population aged >75 presents an interesting challenge with respect to 
vascular access because their overall frailty and vast comorbidity burden make it unlikely 
that the perceived advantages of an AVF will materialize. This is reflected in a mortality 
rate of 30-50% within the first year of dialysis in this population.(27, 38) The beneficial 
aspects of an AVF (i.e. decreased thrombosis, minimal procedural interventions to 
maintain integrity and decreased infectious profile) over an AVG only become evident 
when the use of the AVF exceeds 18 months.(39) Vachharajani et al. retrospectively 
examined an incident octogenarian dialysis population and demonstrated that the vast 
majority of their patients who initiated dialysis with a CVC and subsequently underwent 
AVF placement died before the AVF could mature for cannulation.(40)  Does this 
population really benefit from attempts to construct an AVF or even an AVG? Is a CVC 
sometimes the optimal access for elderly patients with short life expectancy and low 
likelihood of successful AVF maturation? Would many of these patients prefer more 
emphasis on quality of life and less on invasive, often painful interventions with low rates 
of success and unclear survival benefits?  These questions further demonstrate the need 
for a patient-centered approach to vascular access in this age group. Patients and their 
families need to be informed and their opinions then need to be listened to. This is the 
essence of shared decision making and patient centered care. 
 
Multiple observational studies have shown no mortality benefit from AVF or AVG 
compared to a CVC in the elderly population.(41-42). Desilva et al evaluated mortality 
based on initial access type in 115,425 patients aged 67 and older. They demonstrated an 
overall significantly inferior survival in the catheter group but showed no differences in 
survival comparing AVG versus AVF. They further demonstrated a significant benefit 
with AVF over both AVG and CVC among patients aged 67 to 69 years, but outcomes 
with AVF and AVG were similar among patients 80 to 89 years and >90 years.(43) Drew 
and colleagues via a decision analysis method demonstrated that elderly patients have 
little survival benefit with AVFs over AVGs and CVCs.(44) Hicks et al demonstrate that 
AVF is superior to AVG and CVC regardless of the patient's age, including in 
octogenarians. However, they also reported the mortality benefit of AVG over CVC 
might not apply to younger (18-48 years) or older (>89 years) age groups.(45). Of course 
all these analyses are observational and subject to confounding as patients in whom an 
AVF is successfully constructed may be inherently healthier than those in whom AVF is 
either unsuccessful or not even attempted. 
 
Perhaps one of the major arguments against CVCs is related to catheter-related 
bloodstream infections (CRBSI). Given their poor vasculature and propensity for AVF 
immaturity, the elderly population is more likely to have long term CVCs and the 
complications that may arise from their presence. However, reports have demonstrated 
equivocal (46) as well as lower (47) incidence of CRBSI amongst the elderly. 
  
A major consideration in this population is quality of life. Upon commencement of 
dialysis, patients will be subjected to frequent cannulations, long periods of immobility 
during hemodialysis, post-dialysis fatigue and possibly frequent interventions to mature 
and maintain their vascular access. These, in addition to the other co-morbidities, 
physical limitations associated with aging, and polypharmacy may result in an overall 
poor quality of life. Thus, when applying a patient-centered approach to the elderly 
population, the vascular access must be chosen based on their individual characteristics. 
These include prognosis for survival as identified by age, comorbidity scores, functional 
impairments and nutrition status. (4)  
In addition to ESRD, the elderly population faces the burden of chronic kidney disease 
(CKD).  The prevalence of CKD increases with age, from 7.2 percent at ages 65–74 to 
17.0 percent at age 85 and older.(48) This high prevalence of CKD, combined with the 
fact that elderly patients tend to lose renal function at a slower rate than their younger 
counterparts (49) introduces yet another factor to be considered in terms of vascular 
access placement. That is, given their low incidence of progression to ESRD and overall 
shortened survival, the placement of an AVF may subject these patients to the 
complications of surgery with low likelihood of reaping the benefits.(40, 50) O’Hare and 
colleagues studied a cohort of US veterans and found that those who were aged >75 years 
were more likely to die than develop ESRD even when their eGFRs were as low as 15-
29ml/min per 1.73m2.(51) Furthermore, placement of AVFs in all patients aged >75 
years with eGFR <25ml/min per 1.73m2 has been found to result in five unnecessary 
AVFs for every one AVF that was utilized within one year.(49, 51-55)  
Vascular Anatomy  
The Kidney Disease Outcome Quality Initiative (KDOQI) guidelines for hemodialysis 
vascular access (56) recommend that an AVF should be considered first, followed by 
AVG placement if AVF placement is not possible. Catheters should be avoided for HD 
and used only when other options listed are not available. With respect to order of 
creation, the following algorithm is suggested: the initial choice is that of a forearm 
radiocephalic fistula followed by a brachiocephalic fistula with the final option being that 
of a transposed brachiobasilic fistula in those with a failed forearm fistula. Should these 
options fail or be deemed improbable, the creation of a prosthetic AVG should be 
considered with a forearm loop graft preferable to a straight configuration.  
 
Numerous factors contribute to the ideal vascular access. However, perhaps one of the 
most important prerequisites for an appropriate access is suitable vascular anatomy. 
Preoperative evaluation is essential in order to realize the ultimate goal of an ideal access. 
It is via this preoperative evaluation that a sequence of surgical options can be 
determined.(57) Preoperative vascular mapping has been shown to substantially increase 
the total proportion of patients dialyzing with AVFs.(58-61) The minimum criteria for 
venous and arterial diameter that would best support the development of a forearm AVF 
are 2.5 mm and 2 mm, respectively.(62) In addition, the following factors also contribute 
to proper AVF placement: absence of obstruction, stenosis and thrombosis in the venous 
segment, a straight segment for cannulation, location within 1 cm of the skin surface and 
continuity with the central veins.(63)   
 
Despite the algorithm noted in the KDOQI guidelines as well as the known factors 
required for proper AVF creation and development, primary maturation failure of AVFs 
is 30-70%. The highest rate of AVF failures is observed in older patients, female patients, 
African Americans, Hispanics and those with cardiovascular disease.(64) Thus, a patient-
centered approach would offer the possibility of facilitating the appropriate choice of 
vascular access via the incorporation of anatomy along with patient attributes, values and 
preferences, such that the highest probability of usability of an access is made possible.  
 
Verest et al examined the effect of clinical examination and anatomical location on native 
AVF maturation in high-risk patients. They found that a lower arm AVF was a significant 
risk factor for non-maturation and the use of upper arm AVFs if major risk factors are 
present can improve overall maturation rates.(65) They stressed the importance of a 
careful clinical exam together with an integration of risk assessment in planning for an 
AVF. In a similar study, Diskin and colleagues found that the upper arm as the initial site 
for AVF creation was associated with a significantly reduced incidence and prevalence of 
CVC.(66) These two studies challenge the conventional algorithm of access placement 
and stress the need for an overall assessment of the patient’s condition prior to access 
surgery. Woo and colleagues found that the incidence of repeat fistula/graft creation and 
tunneled catheter placement was substantially higher in the first 12 months after fistula 
creation compared with grafts in patients greater than 66 years old.(67) This study has 
been supported by previous evidence suggesting that indiscriminate placement of an AVF 
in elderly patients poorly suited for an AVF will result in numerous AVF-salvaging 
procedures that may or may not be successful and compromise quality of life. (68)   
 
Two groups in whom the benefit of an AVF over an AVG or CVC is less likely include 
those with limited life expectancy (the elderly) and those with poor vasculature (elderly, 
diabetics and females). Lok et al devised risk equations based on the presence of four 
clinical predictors that were associated with failure to mature (FTM). (69) These 
included, age (>65), peripheral vascular disease, coronary artery disease, and white race. 
The four risk categories were low, moderate, high and very high based on total risk score. 
These categories predicted risk of FTM to be 24, 34, 50, and 69%, respectively. It is 
precisely this type of scoring system of personalized risk assessment that is the core of a 
patient-centered delivery of care model. With applying such a model, patients can be 
spared from repeat surgical and interventional procedures and obtain the vascular access 
with the highest probability of use at initiation of renal replacement therapy.  
 
The high primary failure rates and longer maturation times of AVFs lead to prolonged 
catheter use and its complications. While AVGs require more interventions to maintain 
patency than AVFs, when factoring in the high rate of primary failures in AVFs, the 
cumulative patency is virtually equivalent.  
 
While AVFs may be more cost effective when applied to an ideal population, the costs of 
AVFs may exceed those for AVGs, especially when dealing with a population that has a 
high risk of primary AVF failure.(19, 70) The one-size-fits-all model for vascular access 
is associated with multiple shortcomings, both clinical and financial.  
 
Future Direction  
 
The FFCL has fostered excellent progress in the United States with respect to vascular 
access goals. It is via this and other initiatives that CVC use has declined and AVF use 
increased. Use of CVCs in the United States is now similar to that of most European 
countries having the lowest levels of CVC use.(71) However, Europe continues to exceed 
the goals presented in the NKF-KDOQI guidelines with respect to AVF use. Other 
countries with high AVF incidence and low CVC prevalence have examined the subset of 
patients in whom CVCs and AVGs were present. A Brazilian study found that age, 
presence of hypertension and geographic location were factors most associated with 
prolonged catheter use.(72) In Taiwan, AVGs were observed most often in women, 
elderly persons and patients with diabetes.(73) These studies demonstrate that despite 
surpassing the goals for AVF prevalence, there remains a subset of the ESRD population 
in whom catheter elimination and AVF use may be challenging.  
 
The QIP includes type of vascular access as two of the clinical measures for which 
financial penalties are determined. However, this process is devoid of an individualized 
clinical contextual assessment such that a universal standard is applied to a clinically 
heterogeneous population. The University of Michigan Kidney Epidemiology and Cost 
Center, through its contract with the CMS, convened a technical expert panel (TEP) to 
evaluate the existing NQF (National Quality Forum)-endorsed vascular access measures. 
(74) Their specific objectives included: review of the current endorsed NQF vascular 
access measures, that is minimizing use of CVCs as chronic dialysis access and 
maximizing placement of AVFs, revising the vascular access measure set and the 
consideration of potential risk adjustments.  
 
With respect to minimizing the use of catheters, they proposed 2 exclusions: patients with 
limited life expectancy and patients who have exhausted anatomic options for an AVF or 
AVG. A proposed list of conditions that are associated with limited life expectancy was 
developed and included: hospice care, metastatic cancer, and end stage liver or heart 
disease. The TEP further recommended that the 90-days on dialysis requirement be 
removed for determining the patients included in the calculation. The TEP agreed that 
AVFs are the preferred access for most patients, and that AVGs are still preferred to 
CVCs. They recommended that the AVF measure should be adjusted for conditions 
where an AVG might be an acceptable. These conditions included older age, diabetes, 
presence of vascular disease, and high BMI. The TEP further recommended that the AVF 
be counted only if it is being used with two needles and no dialysis catheter is present. It 
might further be suggested that patients’ wishes be taken into account in developing 
metrics. If an elderly or frail patient decides after full education that they do not wish to 
have an AVF placed, is it appropriate to pressure them to do so?  
 
It is these types of alterations to the current metrics that are necessary for the evolution of 
the QIP to make it more consistent with a patient-centered approach to care and avoid the 
placement of AVFs in unsuitable patients.  The vascular access metrics must be aligned 
to encourage patient-centeredness based on medical appropriateness, patient preference, 
and quality of life while still recognizing the results of population studies. 
 
Kliger describes as a balance scorecard approach to ESRD management which 
emphasizes that if CPMs are used to develop physician performance scores which are 
used to calculate physician reimbursement, then they serve not only as a quality 
improvement tool but also a driving force in determining the way care is provided.(75) 
The author further notes that the metrics used for quality reporting were developed from 
population studies of best practice and do not identify opportunities for individualizing 
care, the foundation of a patient-centered approach. His balanced scorecard consists of: 
population based best clinical practice, patient perceptions, and individually crafted 
patient goals of care. Kliger’s concept is further enhanced by Nissenson’s quality 
pyramid with biochemical and surrogate data at the base, moving into mortality, 
hospitalization and patient experience measures moving up the pyramid with the pinnacle 
representing measures of health-related quality of life.(76) 
 
In the patient-centered approach to care the uniqueness of individuals must be understood 
coalescing in a tailored course of treatment. Finkelstein in his discussion of performance 
measures in dialysis facilities emphasizes that physicians must not be obscured by 
arbitrary standards and targets rather focus on tailoring treatment to maximize quality of 
life.(77) It is precisely this methodology that must be applied to vascular access 
management.  Flow diagrams for the selection of vascular access in patients at high risk 
for AVF failure based on age, prognosis, and vascular anatomy are proposed in Figures 3, 
4, and 5, respectively.  
 
In conclusion, while placement of an AVF may be possible in many patients, the 
realization that a subgroup of patients exists who are unsuitable for this particular form of 
vascular access is critical. By applying a patient-centered approach to the conventional 
vascular access algorithm, what results is an approach that lessens the costs and 
physical/mental pain associated with unnecessary surgical and interventional procedures 
with an overall improvement in an individual patient’s quality of life. As nephrologists 
we must ensure that our patients receive the most suitable vascular access based on their 
unique clinical characteristics. It is the responsibility of CMS and the QIP to allow us to 
do so without facing penalty. 
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Table 1. Patient Perspectives on Hemodialysis Vascular Access 
Themes Patient Perspective  
Heightened Vulnerability 
- Bodily intrusion  - Fear of cannulation  - Threat of complications and failure   - Unpreparedness - Dependence on a lifeline - Wary of unfamiliar providers 
Disfigurement 
- Preserving normal appearance  - Visual reminder of disease - Avoiding stigma 
Mechanization of the Body 
- Bonded to a machine  - Internal abnormality - Constant maintenance 
Impinging on Way of Life 
- Physical incapacitation  
- Instigating family tension  
- Wasting time 
- Added expense 
Self-Preservation and Ownership 
- Task-focused control  
- Advocating for protection 
- Acceptance 
Confronting Decisions and Consequences - Imminence of dialysis therapy - Existential thoughts  
From Casey et al. (24) 
 
 
 
 
 
 
 
 
  
Figure 1. 
From DOPPS Dialysis Practice Monitor. (2)  
 
 
 
 
 
 
 
 
 
  
Figure 2. 
Vascular access use during the first year of hemodialysis by time since initiation of 
ESRD treatment, among patients new to hemodialysis in 2012, from the ESRD medical 
evidence form (2728) and CROWNWeb data.  USRDS 2014 Annual Data Report, 
volume 2, figure 3.15.(3) 
 
 
 
 
 
 
 
  
Figure 3. 
Flow diagram for the selection of vascular access in elderly patients. 
AVG = arteriovenous graft; AVF = arteriovenous fistula; TCD = tunneled dialysis 
catheter. 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 
Age >75 
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Flow diagram for the selection of vascular access based on patient prognosis. 
AVG = arteriovenous graft; AVF = arteriovenous fistula. 
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Figure 5. 
Flow diagram for the selection of vascular access based on vascular anatomy. 
AVG = arteriovenous graft; AVF = arteriovenous fistula. 
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